Episurf Medical releases new CE-marked joint visualisation tool based on AI

Episurf Medical (NASDAQ: EPIS B) today announces that the company has CE-marked a new knee joint visualisation tool, which will be released to the European market following a controlled launch process. The tool, named Epioscopy®, is a web-based application based on artificial intelligence (AI), providing an overview of a knee joint’s clinical condition. Epioscopy® is intended to assist healthcare professionals in their planning of optimal treatments for patients’ knees by interactive 3D visualisation of structures and possible structural deviations.

“Clever tuning of medical imaging sequences in combination with automation processes based on artificial intelligence has resulted in stunning anatomical and pathological visualisation. There are no limits within this field and Episurf is definitely a player here” says Dr Adam Mitchell, Consultant Radiologist and member of Episurf Medical’s Clinical Advisory Board.

“This is a significant event for us. Epioscopy® reflects many of the most evident trends in orthopaedics, including computer assisted surgical pre-planning, individualised solutions and minimally invasive approaches. Hence, it is an important product in our positioning for the future. In addition, it brings operational gains as well, as continued development of our technology platform is crucial for us in our work towards securing long-term profitability. This simply means that through Epioscopy®, we can serve our customers in a more efficient and faster way, thereby decreasing costs for everyone” comments Pål Ryfors, CEO, Episurf Medical.

For more  information, please contact:

 Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.10 CEST on 28 September 2018.